Last reviewed · How we verify
Doxycyline
At a glance
| Generic name | Doxycyline |
|---|---|
| Also known as | Doxy-100, Targadox, Oracea |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY) (PHASE3)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- Evaluation of Doxycycline Nanoparticle With Gelatin Sponge on Immediate Implant in Esthetic Region (NA)
- Metformin for the Treatment of Hidradenitis Suppurativa (HS) (PHASE3)
- Effect of Doxycycline in Levodopa Treated Parkinson's Disease Patients (PHASE2)
- Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI (PHASE4)
- Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris (PHASE3)
- Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxycyline CI brief — competitive landscape report
- Doxycyline updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI